The Sarasota, Fla.-based company made its first sale in the new notice on May 15, collecting the more than $2.1 million from eight investors so far. The offering is not being made in connection with a business combination transaction, like a merger or acquisition.
Invo Bioscience still has almost $1.4 million remaining to sell in the offering that is set to total $3.5 million. Separately, the company owes $128,000 in sales commissions related to the offering, according to the filing.
Invo Bioscience makes the InvoCell system for incubating eggs and sperm during fertilization during early embryo development, operating within a woman’s body.